Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xingying Biotechnology

Request full access

Allows live cell drugs eliminate cancer cells

ChinaFounded 2021Biotech & Life Sciences

About Xingying Biotechnology

Neukio Biotherapeutics is a pioneering company in the field of biotechnology, specializing in the development of iPSC-derived CAR-NK cell therapies for cancer treatment. The company operates in the biopharmaceutical market, focusing on creating advanced immunotherapies that leverage the natural abilities of NK (Natural Killer) cells to target and destroy cancer cells. Neukio's primary clients include healthcare providers, research institutions, and pharmaceutical companies seeking cutting-edge cancer treatment solutions.

The business model of Neukio Biotherapeutics revolves around research and development, clinical trials, and eventual commercialization of their proprietary CAR-NK cell therapies. Revenue is generated through partnerships, licensing agreements, and direct sales of their therapeutic products once they receive regulatory approval.

Neukio Biotherapeutics aims to revolutionize cancer treatment by offering innovative, effective, and safe immunotherapy options. The company has secured significant funding to support its research and development efforts, ensuring continuous advancement in their technology platform.

Source: Dealroom company data

At a glance

Status
Operational
Employees
14
Open positions
None listed
Dealroom signal
25.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Sep 2022 $50M $200M IDG Capital · CD Capital · Yahui Investment · Kuanyu Capital ↗
EARLY VCOther financing Jul 2021 $40M $160M Lilly Asia Ventures ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Xingying Biotechnology website traffic

Latest recorded traffic for Xingying Biotechnology is 2.2K monthly website visits, up 197.3% over the last three months. Xingying Biotechnology's team grew 0% over the past year.

Latest monthly visits2.2K 3-month web change+197.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Xingying Biotechnology in its local ecosystem

Live from Dealroom

The Xingying Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Lilly Asia Ventures
  • IDG Capital
  • CD Capital
  • Yahui Investment
  • Kuanyu Capital
  • Eli Lilly
  • Sherpa Venture Partners
Employees 14 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xingying Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xingying Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.